Drugs / VOX
last change Jan 2016 re-read 2 minutes ago

VOX

Developed for
chronic hepatitis C virus infection
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02378961 Feb → Sep 2015 chronic hepatitis C virus infection Gilead Sciences Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VOX ClinicalTrials.gov intervention name — accepted as the source's own label NCT02378961